TY - GEN
T1 - Influence of hydrophobic surface modification of chitosan based methotrexate (MTX) micro implants to treat intraocular lymphoma
AU - Manna, Soumyarwit
AU - Augsburger, James J.
AU - Correa, Zelia M.
AU - Landero, Julio A.
AU - Banerjee, Rupak K.
PY - 2013
Y1 - 2013
N2 - Primary intraocular lymphoma (PIOL) is a rare form of lymphoma which is encountered in ocular oncology practice. Most preferred treatment has been intravitreal MTX injections which do not have a long lasting chemotherapeutic effect due to rapid elimination of the drug. In this study, chitosan (CS) and polylactic acid (PLA) based intraocular implants are fabricated for different MTX loadings (10%, 25% and 40% w/w). The implants administer a therapeutic dosage of 0.2-2.0 μg/day of MTX over a period of a month. PLA coated CS-MTX implants can be used for sustained release of MTX, thereby improving the treatment of PIOL.
AB - Primary intraocular lymphoma (PIOL) is a rare form of lymphoma which is encountered in ocular oncology practice. Most preferred treatment has been intravitreal MTX injections which do not have a long lasting chemotherapeutic effect due to rapid elimination of the drug. In this study, chitosan (CS) and polylactic acid (PLA) based intraocular implants are fabricated for different MTX loadings (10%, 25% and 40% w/w). The implants administer a therapeutic dosage of 0.2-2.0 μg/day of MTX over a period of a month. PLA coated CS-MTX implants can be used for sustained release of MTX, thereby improving the treatment of PIOL.
UR - http://www.scopus.com/inward/record.url?scp=84894660940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894660940&partnerID=8YFLogxK
U2 - 10.1115/SBC2013-14414
DO - 10.1115/SBC2013-14414
M3 - Conference contribution
AN - SCOPUS:84894660940
SN - 9780791855614
T3 - ASME 2013 Summer Bioengineering Conference, SBC 2013
BT - ASME 2013 Summer Bioengineering Conference, SBC 2013
T2 - ASME 2013 Summer Bioengineering Conference, SBC 2013
Y2 - 26 June 2013 through 29 June 2013
ER -